230615-69-7

Basic information

• Product Name: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine
• Synonyms: 1-(4,5-Diamino-10-aza-tricyclo[6.3.1.0]dodeca-2,4,6-trien-10-yl)-2,2,2-trifluoro-ethanone;1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI);1-(7,8-diamino-1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-2,2,2-trifluoroethanone;2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine;1-(7,8-diaMino-4,5-dihydro-1H-1,5-Methanobenzo[d]azepin-3(2H)-yl)-2,2,2-trifluoroethanone;Ethanone,1-(7,8-diamino-1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-2,2,2-trifluoro-
• CAS NO: 230615-69-7
• Molecular Formula: C13H14F3N3O
• Molecular Weight: 285.26
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 230615-69-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 83-88°C
• Boiling Point: 487.739 °C at 760 mmHg
• Flash Point: 248.776 °C
• Appearance: Brownish orange solid
• Density: 1.455
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: 4.86±0.20(Predicted)
• CAS DataBase Reference: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine(230615-69-7)
• EPA Substance Registry System: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine(230615-69-7)

Safety Data

• Hazardous Substances Data: 230615-69-7(Hazardous Substances Data)

Usage

Uses

Varenicline intermediate.

InChI:InChI=1/C13H14F3N3O/c14-13(15,16)12(20)19-4-6-1-7(5-19)9-3-11(18)10(17)2-8(6)9/h2-3,6-7H,1,4-5,17-18H2

Upstream product

• 230615-59-5 1-(7,8-dinitro-4,5-dihydro-1H-1,5-methanobenzo[d]azepin-3(2H)-yl)-2,2,2-trifluoroethanone 

Downstream Products

• 230615-70-0 1-(5,8,14-triazatetracyclo[10.3.1.0^2,11.0^4,9]hexadeca-2,4,6,8,10-pentaen-4-yl)-2,2,2-trifluoroethanone 
• 230615-70-0 1-(9,10-dihydro-6H-6,10-methanoazepino[4,5-g]quinoxaline-8(7H)-yl)-2,2,2,-trifluoroethanone 
• 357426-10-9 C₁₅H₁₂F₃N₃O₂ 

Relevant articles and documents

Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation

Herein we describe a novel series of compounds from which varenicline (1, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) has been identified for smoking cessation. Neuronal nicotinic acetylcholine receptors (nAChRs) mediate the dependence-producing effects of nicotine. We have pursued α4β2 nicotinic receptor partial agonists to inhibit dopaminergic activation produced by smoking while simultaneously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts. Varenicline displays high α4β2 nAChR affinity and the desired in vivo dopaminergic profile.

Hydrogenation of a pharmaceutical intermediate by a continuous stirred tank reactor system

A proof of concept study on the continuous hydrogenation of a pharmaceutical intermediate is presented. A slurry feed of CP- 548495, a dintro intermediate in a smoking cessation drug, was reduced in a two-reactor continuous stirred tank train to the diami

Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof

Provided is a cocrystal of varenicline and oxalic acid. In particular, provided is a cocrystal of varenicline and oxalic acid of formula (I) having a molar ratio of varenicline to oxalic acid of 1:1.5. Also provided is a process for preparing the cocrystal, a pharmaceutical composition containing the cocrystal and a method of using the cocrystal and pharmaceutical composition, such as for reducing nicotine addiction or tobacco use.

AN IMPROVED PROCESS FOR THE PREPARATION OF VARENICLINE AND SALT THEREOF

of the Invention The present invention relates to an improved process for the preparation of varenicline and salt thereof. The present invention also provides a process for the 2,7preparation of l-(4,5-dinitro-10-aza-tricyclo[6.3.1.0 ]dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoroethanone of Formula 4 using ethyl trifluoroacetate and further converted to varenicline and salt thereof.